Christopher W. Cain - Jun 5, 2024 Form 4 Insider Report for Cogent Biosciences, Inc. (COGT)

Role
Director
Signature
/s/ Evan D. Kearns, Attorney-in-Fact
Stock symbol
COGT
Transactions as of
Jun 5, 2024
Transactions value $
$0
Form type
4
Date filed
6/13/2024, 07:18 PM
Previous filing
Jun 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COGT Stock Option (Right to Buy) Award $0 +44.7K $0.00 44.7K Jun 5, 2024 Common Stock 44.7K $8.92 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders.
F2 Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.